Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Kyverna Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed negative information regarding its business and clinical trials, which significantly impacted its stock price after the Initial Public Offering [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Kyverna securities on or after February 8, 2024, with a deadline to file a lead plaintiff motion by February 7, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Kyverna - The Complaint claims that Kyverna made materially false and misleading statements and failed to disclose critical data from its clinical trials that could negatively affect its lead product [3]. - The undisclosed negative findings had a substantial impact on the company's prospects, making the information in the Registration Statement and Prospectus misleading [3]. Group 3: Stock Price Impact - Following the revelation of the undisclosed information, Kyverna's stock price fell significantly, dropping to as low as $3.92 per share, which represents a decline of over 82% from the $22 IPO Offering Price [4].